Dyne Therapeutics, Inc. (DYN) announced that DYNE-251, an investigational therapeutic for Duchenne muscular dystrophy mutations amenable to exon 51 skipping, was granted FDA orphan drug and rare pediatric disease designations. DYNE-251 is being evaluated in the Phase 1/2 DELIVER clinical trial.
Under the FDA's rare pediatric disease designation program, the FDA may grant a priority review voucher to a sponsor who receives a product approval for a rare pediatric disease.
Wildon Farwell, chief medical officer of Dyne, said: "We continue to advance our DELIVER clinical trial and look forward to sharing initial clinical data later this year."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News